The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Launched by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK) · Feb 14, 2019

Keywords

ClinConnect Summary

This clinical trial is examining a new way to measure the best dose of radioactive iodine treatment for patients with advanced differentiated thyroid cancer. It compares two methods of preparing patients for this treatment: one involves stopping thyroid hormone medication, which can cause low thyroid hormone levels, and the other uses an injection of a special hormone to avoid this side effect. The study aims to see how well a specific type of imaging (called 124-I-PET/CT) can help determine not only the maximum safe dose of the treatment but also how effectively it might target cancerous areas.

To participate, patients must be at least 18 years old and have a confirmed diagnosis of thyroid cancer that has spread, as indicated by certain imaging tests. They should have undergone surgery to remove their thyroid gland and may need repeated treatments with radioactive iodine. Throughout the study, participants will undergo imaging tests and receive treatment based on their individual dosimetry calculations, with follow-up appointments scheduled for five years. This trial is currently recruiting participants and aims to include 30 individuals with high-risk thyroid cancer.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• * Patients with established thyroid cancer diagnosis based on the pathology report reviewed at the National Institutes of Health, who:
• • underwent total thyroidectomy plus or minus neck lymph node dissection as clinically indicated,
• • are presenting with known per structural imaging (US neck, CT or MRI neck/chest/abdomen/pelvis) persistent/recurrent disease either locally advanced or presenting with distant metastases; or
• • are presenting with suspected persistent/recurrent locoregional or distant metastases based on the high risk features such as advanced tumor per pathology report (tumor size \>4 cm, exrathyroidal extension, higher risk pathology such as tall cell, columnar cell, poorly differentiated variant, follicular thyroid cancer with gross vascular invasion, positive margins after the surgery, bulky lymphadenopathy in the central and/or lateral neck), detectable/increasing baseline/suppressed thyroglobulin (Tg) level or detectable/increasing anti-Tg antibody titers if anti-Tg antibodies are present.
• • are either RAI -naive or requiring repeated RAI therapy for locally advanced disease or distant metastases or underwent therapy with BRAF inhibitor (dabrafenib or vemurafenib\*) or selumetinib\*\* for at least 4 weeks that may re-induce RAI uptake.
• • Underwent imaging with either a CT or MRI of the brain and spine with gadolinium contrast to screen for the brain/spine metastases.
• • Age greater than or equal to 18 years of age.
• • 24 hour urine iodine excretion of less than or equal to 150 micro grams/24 hour.
• • BRAF inhibitors are recommended by 2021 NCCN guidelines as one of the management options for BRAF mutant tumors(13,14)
• • Selumetinib has an FDA orphan drug designation for adjuvant treatment of metastatic thyroid cancer to re-induce RAI uptake
• EXCLUSION CRITERIA:
• • -Patients with RAI-non avid disease documented by negative post-therapy whole body scans performed after previous RAI treatments and not subjected to re-differentiation therapy.
• • Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma, severe depression which might be exacerbated by thyroid hormone withdrawal.
• • Patients with spinal or brain metastases as they are at risk of TSH-stimulation induced swelling of metastatic lesions leading to potentially detrimental side effects. These patients will be evaluated per the standard of care protocol 77-DK-0096.
• • Pregnant or lactating women per self report.
• • Adults who are incapable of providing informed consent.